Kriya Therapeutics is a biopharmaceutical startup that specializes in gene therapy. The company's main objective is to develop innovative treatments for prevalent diseases that affect millions of people worldwide and for which there are currently no effective treatments. Kriya operates in the biotechnology and healthcare markets, serving patients suffering from diseases such as Geographic Atrophy, Noninfectious Uveitis, Diabetic Retinopathy, Trigeminal Neuralgia, and Nonalcoholic Steatohepatitis (NASH).

The company's business model revolves around the development and commercialization of gene therapies. They generate revenue through the licensing and collaboration agreements with other companies, as well as through the potential sales of their gene therapies once they are approved for use. For instance, Kriya recently announced an exclusive license and collaboration agreement with Everads to advance gene therapies for prevalent diseases in Ophthalmology.

Kriya has been successful in securing significant private investment since its inception in 2019, with over $600 million raised. This includes a recent addition of $150 million to its Series C funding round, bringing the total for that round to over $430 million. The funds are used to further its mission of delivering gene therapies for prevalent diseases.

The company is based in Palo Alto, California, and Research Triangle Park, North Carolina, and is backed by top healthcare and technology investors. The team comprises exceptional scientists, operators, and entrepreneurs committed to building the world's leading gene therapy biopharmaceutical company.

Keywords: Gene Therapy, Biopharmaceutical, Prevalent Diseases, Licensing and Collaboration, Private Investment, Healthcare Market, Biotechnology Market, Geographic Atrophy, Nonalcoholic Steatohepatitis (NASH), Diabetic Retinopathy.